researchbhaskar

1. WEEKLY PREMIUM REPORT 10/6/2019 TO 14/6/2019 www.researchbhaskar.com http://www.ways2star.in

2. CONTENTS • INDIAN MARKET OVERVIEW • MARKET OVERVIEW • NIFTY & BANK NIFTY OVERVIEW • LAST WEEK MAJOR UPDATE • RESEARCH BHASKAR LAST WEEK • ACHIEVEMENT http://www.ways2star.in

3. INDIAN MARKET OVERVIEW • Sensex was down 289.29 points at 39,452.07, while Nifty was down 90.70 points at 11,823.30. About 808 shares have advanced, 1686 shares declined, and 144 shares are unchanged.  • IndusInd Bank, Zee Entertainment, Indiabulls Housing, BhartiAirtel and Axis Bank were the top losers on the Nifty, while gainers were BhartiInfratel, Sun Pharma, Power Grid, L&T and Vedanta. • All the sectoral indices ended lower led by FMCG, bank, auto, pharma, infra, metal, IT and energy. http://www.ways2star.in

4. LAST WEEK MAJOR UPDATES • HEXAWARE • Hexaware Technologies Inc., a wholly owned subsidiary of Hexaware Technologies, India has acquired 100% shares of Mobiquity Inc. and Hexaware Technologies has acquired 100% shares of MobiquitySoftech (wholly owned subsidiary of Mobiquity Inc.) • “The acquisition of Mobiquity fits in perfectly into our three-pronged strategy of adopting automation, cloud and customer experience transformation. While our capabilities are already quite evolved in the areas of automation, the new acquisition will help us augment our capabilities in cloud and customer experience transformation,” http://www.ways2star.in

5. HEXAWAREAFTER NEWS

6. LAST WEEK MAJOR UPDATES DRREDDY The company has entered into a definitive asset purchase agreement with Upsher-Smith Laboratories, LLC (Upsher-Smith), pursuant to which Dr. Reddy's would sell its US and select territory rights for ZEMBRACE SYMTOUCH (sumatriptan injection) 3 mg and TOSYMRA (sumatriptan nasal spray) 10 mg, which are commercialized through its wholly owned subsidiary, PromiusPharma, LLC. 

7. DRREDDYAFTER NEWS

8. LAST WEEK MAJOR UPDATES • DR LAL PATHLABS • Diagnostic chain Dr LalPathLabs on Friday said its board has approved the acquisition of 70% stake in a new company to be incorporated by Vinita Kothari and SushilaDalal for a cash consideration not exceeding ₹50 crore. • The company's wholly-owned subsidiary, Pathlabs Unifiers Pvt Ltd has decided to acquire 70% of businesses of Central Lab, Indore and M/s 'Vinita Kothari', a proprietorship concern of Kothari, through a new company to be incorporated for strengthening its business presence in Madhya Pradesh, Dr LalPathLabs said in a filing to BSE. • Dr LalPathLabs' board has approved the signing a binding term sheet for the acquisition. • Central Lab, Indore, is engaged in pathology business, and is a partnership concern having Kothari and Dalal as its partners, it added. • The indicative time period for completion of the acquisition is within three months, Dr LalPathLabs said. • The new company will be engaged in healthcare/diagnostic services in Madhya Pradesh and adjoining areas and shall house the business of Central Lab, Indore, and proprietorship concern .

9. DR LAL PATHLABSAFTER NEWS

10. NIFTY OVERVIEW http://www.ways2star.in

11. BANK NIFTY OVERVIEW http://www.ways2star.in

12. LAST WEEK MAJOR UPDATES RUPEE • The rupee traded lower by 4 paise at 69.55 against the US dollar, as rising crude oil price concerns weighed on investor community. • Rupee is trading in a narrow range as prospects of an interest rate cut by the US Federal Reserve kept investors edgy. • Besides, strengthening of the American currency in the overseas market and weak opening in domestic equities weighed on the local unit. http://www.ways2star.in

13. LAST WEEK MAJOR UPDATES CRUDEOIL Oil fell on Friday after sharp gains in the previous session when prices were boosted after attacks on two oil tankers in the Gulf of Oman stoked concerns of reduced crude flows through one of the world's key shipping routes.

14. DISCLAIMER • The information contained here was gathered from sources deemed reliable however; no claim is made as to accuracy or content. This does not contain specific recommendations to buy or sell at particular prices or time, nor should any examples presented be deemed as such. There is a risk of loss in commodity trading and you should carefully consider your financial position before making a trade. This is not, nor is it intended, to be a complete study of chart patterns or technical analysis and should not be deemed as such. WAYS2STAR does not guarantee that such information is accurate or complete and it should not be relied upon as such. Any opinions expressed reflect judgments at this date and are subject to change without notice. For use at the sole discretion of the investor without any liability on WAYS2STAR Research. http://www.ways2star.in

15. WWW.WAYS2STAR.IN THANK YOU ………!!!!! CONTACT DETAILS • Ways2star Financial Services SebiReg Inh00001402 • Research Analyst • Chetanshukla • con- 0731-4989454 • 126, 1st Floor,Xth Central Mall, Mahavir Nagar, Kandivali (West), MUMBAI, MAHARASHTRA, 400067 • Mail-Info@ways2star.in • www.ways2star.in